- Home
- AMIX
as 12-23-2024 10:30am EST
Stocks
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 7.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 188.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.88 - $152.00 | Next Earning Date: | 02-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest AUTONOMIX MEDICAL INC News
AMIX Breaking Stock News: Dive into AMIX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 hours ago
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
GlobeNewswire
4 days ago
Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality
GlobeNewswire
18 days ago
Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
GlobeNewswire
a month ago
Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
GlobeNewswire
a month ago
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
GlobeNewswire
a month ago
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
2 months ago
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
GlobeNewswire
2 months ago
Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
Compare AMIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMIX AUTONOMIX MEDICAL INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.